Enhanced Survival in Patients With Multiple Primary Melanoma

Doubrovsky, Anna; Menzies, Scott W.

doi:10.1001/archderm.139.8.1013

Cited by 73 publications

(129 citation statements)

References 23 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…28,29 Current Australian clinical practice guidelines 23 recommend that teaching skin self-examination should be a high priority in follow-up care for people with invasive melanoma; our results suggest that this should be extended to include those with an in situ melanoma. It would seem reasonable to suggest that survival would decrease with a greater number of primary invasive melanomas, but studies 30,31 examining the effect of multiple primary melanomas on survival have not supported this view. A recent report from the Genes, Environment, and Melanoma Study 30 found no significant difference in prognosis between patients with single vs multiple primary invasive melanomas after adjusting for other factors.…”

Section: Discussionmentioning

confidence: 99%

Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010

et al. 2014

View full text Add to dashboard Cite

show abstract

“…3,4,23 In a retrospective analysis on 5250 patients with melanoma that was controlled for known prognostic factors as well as ''survival bias'' (because patients who survive longer have the opportunity to develop additional tumors), the authors observed that patients who had !3 primary melanomas had longer survival than patients who had a single primary melanoma. 23 In another study, Ferrone et al suggested that less aggressive disease biology may be the reason for a higher percentage of disease-specific deaths in patients with SPM than in patients with MPM and also may be the reason for significantly thinner initial melanomas in patients with MPM versus patients with SPM. 12 We chose to examine tumor mitotic rate, a measure of proliferation, as a surrogate for biologic aggression.…”

Section: Discussionmentioning

confidence: 99%

“…39 A controversial hypothesis to explain the enhanced survival of patients with MPM is an ''immunization effect,'' which proposes that there is an immune response in patients with MPM to each subsequent melanoma. 23,40,41 It is believed that cytotoxic T-lymphocytes may recognize common tumor antigens and subsequently may lead to the regression of melanoma. However, in a recent histopathologic study of melanomas from 18 patients with MPM, Zoller et al observed no difference in the incidence of regression between the first and second melanomas, leading those authors to conclude that the ''immunization effect'' may not occur in patients with MPM.…”

Section: Discussionmentioning

confidence: 99%

“…12 In addition, the prognosis for patients with MPM may be better than that for patients with SPM. 23 The mitotic rate (defined as mitoses/mm 2 ) of the primary tumor can serve as a measure for tumor proliferation and has been identified as an independent, adverse predictor of survival in patients with cutaneous melanoma. 24,25 The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for melanoma now uses a mitotic rate of at least 1 mitosis/mm 2 as a primary criterion for defining stage T1b melanoma, replacing the former criterion of Clark level of invasion, because studies have demonstrated that an increasing mitotic rate is associated with declining survival rates, particularly within thin melanoma subgroups.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Single versus multiple primary melanomas

Hwa

Price

Belitskaya-Lévy

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:In patients with multiple primary melanomas (MPM), mean tumor thickness tends to decrease from the first melanoma to the second melanoma, and prognosis may be improved compared with the prognosis for patients who have a single primary melanoma (SPM). In this study, the authors compared the clinicopathologic features of patients with MPM and SPM to better characterize the differences between these 2 groups and to determine whether or not there is an inherent difference in tumor aggression. METHODS: In total, 788 patients with melanoma who were enrolled prospectively in the Interdisciplinary Melanoma Cooperative Group database from 2002 to 2008 were studied. Patients with SPM and with MPM were compared with regard to clinical and primary melanoma characteristics. RESULTS: Of 788 patients with melanoma, 61 patients (7.7%) had 2 or more primary melanomas. The incidence of developing a second primary melanoma 1 year and 5 years after initial melanoma diagnosis was 4.1% and 8.7%, respectively, and most of the risk accumulated within the first year. The incidence of MPM was greater in patients aged !60 years than in those aged 60 years. The absence or presence of mitosis and other tumor characteristics did not differ significantly between patients with SPM and patients with MPM (P ¼ .61). CONCLUSIONS: No difference was observed in the presence or absence of mitoses, a marker of tumor proliferation, in SPM and MPM. Because it has been demonstrated that the presence of mitosis is a powerful prognostic marker, the current findings suggested that the tumors behave similarly in patients with SPM and patients with MPM. The authors concluded that differences in tumor thickness and prognosis between SPM and MPM more likely are caused by factors other than tumor biology, such as increased surveillance. Cancer 2012;118:4184-92.

show abstract

“…However, tumors from diverse origin can also occur as multiple primary lesions, and the skin is no exception to this [7]. Some research results have (Lesion 3) The remaining histological material conforms to dermal melanocytic nevi, Type 1 with none found or with a minimum cytological atypical features and a zonal migration within the framework of the papillary and reticular networks of the dermal component/ migration estimation based on parameters between 0.98 and 1.07 mm.…”

Section: Discussionmentioning

confidence: 99%

Multiple primary cutaneous melanomas in patients with FAMMM syndrome and sporadic atypical mole syndrome (AMS): What’s worse?

Tchernev

Ananiev

Cardoso

et al. 2014

Wien Med Wochenschr

View full text Add to dashboard Cite

Atypical Mole Syndrome is the most important phenotypic risk factor for cutaneous melanoma, a malignancy that accounts for about 80% of deaths from skin cancer. Since early diagnosis of melanoma is of great prognostic relevance, the identification of Atypical Mole Syndrome carriers (sporadic and familial) is essential, as well as the recommendation of preventative measures that must be undertaken by these patients.We report two rare cases concerning patients with multiple primary skin melanomas in the setting of a familial and a sporadic syndrome of dysplastic nevi: the first patient is a 67-year-old patient with a history of multiple superficial spreading melanomas localized on his back. The second patient presented with multiple primary melanomas in advanced stage in the context of the so-called sporadic form of the syndrome of dysplastic nevi-AMS (atypical mole syndrome). In the first case, excision of the melanomas was carried out with an uneventful post-operative period. In the second case, disseminated metastases were detected, involving the right fibula, the abdominal cavity as well as multiple lesions in the brain. The patient declined BRAF mutation tests as well as chemotherapy or targeted therapies, and suffered a rapid deterioration in his general condition leading to death. We classified the second case as a sporadic form of the atypical mole syndrome, associated with one nodular and two superficial spreading melanomas.There are no data in the literature to allow us to understand if, in patients with multiple primary melanomas, there is any difference in terms of prognosis between those with and without a family history of a similar phenotype. To answer this and other questions related to these rare cases, further studies with a significant number of patients should be carried out.

show abstract

Enhanced Survival in Patients With Multiple Primary Melanoma

Cited by 73 publications

References 23 publications

Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010

Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010

Single versus multiple primary melanomas

Multiple primary cutaneous melanomas in patients with FAMMM syndrome and sporadic atypical mole syndrome (AMS): What’s worse?

Contact Info

Product

Resources

About